Borrelia burgdorferi — the bacterium behind Lyme disease — has a vulnerability that most pathogens do not: it is microaerophilic. It thrives in low-oxygen environments and is directly inhibited by elevated oxygen. That biological fact, combined with the systemic anti-inflammatory and mitochondrial-restorative effects of hyperbaric oxygen therapy, gives HBOT a uniquely strong rationale for chronic Lyme disease and post-treatment Lyme disease syndrome (PTLDS) — conditions that often fail to respond to antibiotics alone.
The Science: Direct Antimicrobial Action
The case for HBOT in Lyme disease begins with simple microbiology. Borrelia burgdorferi grows best in low-oxygen environments. In vitro, exposure to elevated oxygen tensions kills or arrests the spirochete. This isn’t theoretical — it’s been demonstrated in multiple lab studies dating back to the 1990s.
Pressurized oxygen via HBOT achieves what oral antibiotics often cannot: it raises tissue oxygen concentrations in the deep, poorly-perfused regions where Borrelia tends to persist — joints, connective tissue, and the central nervous system. The drug doesn’t have to find the bacterium; the oxygen reaches it.
Beyond the direct antimicrobial effect, HBOT addresses the secondary problems that drive most chronic Lyme symptoms:
– Mitochondrial dysfunction. Borrelia and its toxins damage mitochondria, which is part of why patients report profound fatigue. HBOT promotes mitochondrial recovery.
– Chronic neuroinflammation. Persistent immune activation in the CNS is a major driver of “brain fog,” cognitive impairment, and depression in chronic Lyme. HBOT downregulates this.
– Compromised microcirculation. Lyme can damage small blood vessels. HBOT drives angiogenesis and improves perfusion.
– Biofilm penetration. Borrelia forms biofilms that are highly antibiotic-resistant. Elevated oxygen can disrupt biofilm structure.
The Clinical Evidence
The evidence base for HBOT in Lyme is genuinely thin — partly because chronic Lyme itself is contested in mainstream medicine, which has slowed funding for trials. No dedicated randomized controlled trial of HBOT for Lyme disease has been published to date. Frequently-cited lay-press references to large case series have not matched specific PubMed-indexed peer-reviewed publications, so this page is restricted to the closest verified analog in the literature.
### Efrati et al., PLoS ONE (2015) — Fibromyalgia (closest analog)
A 60-patient prospective crossover trial in female fibromyalgia patients (a population that overlaps substantially with the chronic Lyme presentation — mitochondrial dysfunction, chronic neuroinflammation, microcirculatory impairment, frequent prior fibromyalgia diagnosis before serological Lyme confirmation). Protocol: 40 sessions at 2.0 ATA, 90 minutes, 5 days/week. The dolorimeter pain threshold tripled following HBOT, tender-point count reduced by a factor of 2 (treated) and 3 (crossover), and SPECT imaging documented rectification of abnormal brain activity. The control (no-treatment) period produced no improvement, which serves as a strong within-trial null comparator. This is the strongest verified peer-reviewed analog for HBOT in chronic-fatigue-cluster conditions; it is NOT a Lyme-specific trial.
### Why no Lyme-specific RCT yet
Three structural reasons: (1) the chronic-Lyme diagnostic category itself is contested in mainstream medicine, which has slowed trial funding; (2) the population is heterogeneous (varying tick-borne co-infections, varying time-since-infection, varying prior antibiotic exposure), making controlled trial design difficult; (3) HBOT delivery infrastructure is concentrated in academic clinical settings that have not historically prioritized this patient population. A growing number of Lyme-literate clinicians use HBOT in practice, but the formal evidence remains in the case-report and clinical-observation tier — not yet at the level of randomized controlled trials.
### Real-World Use
A growing number of Lyme-literate clinicians now incorporate HBOT into chronic Lyme protocols, often combined with:
– Targeted antibiotic regimens (Dr. Burrascano-style protocols)
– Herbal antimicrobials
– Mitochondrial support (CoQ10, NAD+, B vitamins)
– Detoxification support
The mechanistic case is strong; the formal trial-grade evidence is not yet in the literature. Decisions about HBOT for chronic Lyme should be made jointly with a Lyme-literate physician with full transparency about the evidence tier.
The Lyme Protocol
### The Standard Lyme Protocol
– Pressure: 1.5 ATA (home use); 2.0 ATA (clinical use)
– Oxygen concentration: 95–100%
– Session length: 60 minutes
– Cadence: 5 sessions per week
– Duration: 40 sessions for the initial course; many patients benefit from a second course
### Combining HBOT with Antibiotic Treatment
There is mechanistic logic — though no controlled-trial confirmation — that HBOT may enhance the effectiveness of certain antibiotics, particularly those active against intracellular and biofilm-protected forms of Borrelia. Many Lyme-literate physicians time HBOT sessions to coincide with active antibiotic protocols.
### Herxheimer Reactions
Patients with high bacterial load may experience temporary worsening of symptoms (Herxheimer reactions) during early HBOT sessions, similar to what occurs with effective antibiotic therapy. This is generally interpreted as a sign that bacterial die-off is occurring. Most experienced clinicians manage this by starting with shorter sessions and titrating up.
Practical Considerations for Chronic Lyme Patients
Patients in the chronic Lyme population often face several practical complications that deserve consideration before starting HBOT.
### Sensitivity and Reaction Patterns
Chronic Lyme patients tend to be highly sensitive to interventions of all kinds. They often report strong reactions to small medication doses, supplements, and even dietary changes. Most experienced practitioners therefore start chronic Lyme patients at:
– 1.3 ATA for the first 5–10 sessions
– 30–45 minute sessions initially, increasing to 60 minutes as tolerated
– 3 sessions per week initially, increasing to 5 only if well-tolerated
This conservative ramp respects the population’s sensitivity while still moving toward a clinically meaningful dose.
### Co-Infections
Many chronic Lyme patients also carry co-infections — Babesia, Bartonella, Mycoplasma, viral reactivations like EBV. HBOT may affect these differently. Babesia, for instance, is also oxygen-sensitive and may respond to HBOT; Bartonella less so. A Lyme-literate physician can help interpret response patterns.
### Detoxification Support
Bacterial die-off releases endotoxins and inflammatory debris that the body must clear. Adequate hydration, binders (where appropriate), liver support, and lymphatic movement are routinely paired with HBOT in this population.
HBOT for Chronic Fatigue and Post-Viral Syndromes
The same biological mechanisms that make HBOT effective for chronic Lyme apply to a broader category of post-infectious chronic fatigue syndromes:
– Chronic Fatigue Syndrome / ME
– Long COVID
– Post-viral fatigue (Epstein-Barr, mold-related illness)
– Fibromyalgia
What unites these conditions is a pattern of mitochondrial dysfunction, chronic neuroinflammation, and microcirculatory impairment — exactly the constellation HBOT addresses. While the evidence for each is at different stages of maturity, the mechanistic case is consistent.
> A 2022 small RCT in Long COVID patients showed significant improvements in fatigue and cognition after 40 sessions at 2.0 ATA.
For patients in the chronic fatigue cluster, HBOT is one of the few interventions with both a credible mechanism and clinical signal.
The dolorimeter pain threshold tripled following HBOT, with SPECT imaging documenting rectification of abnormal brain activity in fibromyalgia patients — the closest verified analog to the chronic-Lyme presentation in the peer-reviewed literature.
— Efrati et al., PLoS ONE (2015)